 Well, this year at Ash 2023, there are several important updates. There are some about treatment, but I also really liked an update on diagnostics. And that was an oral presentation by a small company, and they are developing a test for lab light chains that can predict if these light chains are forming amyloids or not. And this can really help in the early diagnosis of AL amyloid doses. So that's an important oral presentation that I saw. The data is too fresh to not be enough to be implemented yet, but I think in the coming years we will hear much more about that. So May You Stage 3 cardiac AL amyloid doses means that your heart is involved with the amyloid. So you have lots of amyloid in your heart, and it's the worst stage you can have. So 3B means that your survival is really poor because your heart failure is really, really bad. And we stage those patients with biomarkers in the blood. So you have a very high NT, ProBMP level and an elevated troponin T or I level in the blood. So the EMN22 clinical trial was a trial especially for these cardiac stage 3B patients. And what we did, we gave them their 200 monotherapy and the primary endpoint of this study was to improve the overall survival. So we didn't look at responses at all, but we said the main point is that with this worst survival that these patients have, we must improve it. So we in the trial ended up with the final result indeed that we improved the survival from historical 5 months to now 10 months. Like I just explained, the overall survival improved and we did see that still in the beginning patients with cardiac stage 3B amyloid doses, they don't tolerate treatment that well. So we did see in the beginning that we lost patients due to cardiac complications. But later on, most patients did respond on therapy and also many patients could fulfill the two-year treatment that was in the protocol. So the side effects of the darotumab are mostly infectious and they are mostly treatable and did not lead to stopping any of the therapy. But the other side effects were indeed heart failure or cardiac fibrillation or other cardiac problems that are not due to the drug but is due to the disease in the advanced stage. So this is very exciting. Darotumab is a kind of immune therapy. And like in myeloma, also in AL-amyloid doses, we're moving to the next step of immune therapy and that these are the biospecific antibodies. And there are some posters here at the hospital, already publications about the use of tyclistoma. That's an anti-BGMA, biospecific antibody, and its use in AL-amyloid doses. And it's working so great. You have nearly 100% response rates, patients tolerate it very good. But one of the side effects of that drug is cytokine release syndrome. And that can be dangerous to your heart, can be dangerous to patients. You can have a low blood pressure with that syndrome. So at the moment, we really pick out the best patients that can tolerate that and that are not the 3B patients but patients with less heart involvement, for example. They were tested in these small retrospective cohorts. But the data are looking very promising. And now we're working very hard in European amyloid doses field to have a prospective trial with these type of drugs, for example, for relapsed patients because we are really excited about the data.